Departments of Neurology and Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA.
Sci Transl Med. 2011 Oct 19;3(105):105ra105. doi: 10.1126/scitranslmed.3002884.
As survival rates of preterm newborns improve as a result of better medical management, these children increasingly show impaired cognition. These adverse cognitive outcomes are associated with decreases in the volume of the cerebellum. Because animals exhibit reduced preterm cerebellar growth after perinatal exposure to glucocorticoids, we sought to determine whether glucocorticoid exposure and other modifiable factors increased the risk for these adverse outcomes in human neonates. We studied 172 preterm neonatal infants from two medical centers, the University of British Columbia and the University of California, San Francisco, by performing serial magnetic resonance imaging examinations near birth and again near term-equivalent age. After we adjusted for associated clinical factors, antenatal betamethasone was not associated with changes in cerebellar volume. Postnatal exposure to clinically routine doses of hydrocortisone or dexamethasone was associated with impaired cerebellar, but not cerebral, growth. Alterations in treatment after preterm birth, particularly glucocorticoid exposure, may help to decrease risk for adverse neurological outcome after preterm birth.
由于更好的医疗管理提高了早产儿的存活率,这些孩子的认知能力受损的情况越来越多。这些不良的认知结果与小脑体积的减少有关。由于动物在围产期接触糖皮质激素后表现出早产的小脑生长减少,我们试图确定糖皮质激素暴露和其他可改变的因素是否会增加人类新生儿出现这些不良结果的风险。我们通过在接近出生时和接近足月时进行连续磁共振成像检查,对来自不列颠哥伦比亚大学和加利福尼亚大学旧金山分校的两个医学中心的 172 名早产儿进行了研究。在我们调整了相关的临床因素后,产前倍他米松的使用与小脑体积的变化无关。在早产儿出生后接触到临床常规剂量的氢化可的松或地塞米松与小脑生长受损有关,但与大脑生长无关。早产儿出生后治疗方法的改变,特别是糖皮质激素的使用,可能有助于降低早产儿出生后不良神经结局的风险。